We invite you to view the archived recording of the virtual review webinar which was held on May 14th and led by Dr. Vipul Jairath (CIBRN Chair) featuring the March 2018 article by Strik et al in The Lancet Gastroenterology & Hepatology: “Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial” [article abstract]
Click to view video: http://bit.ly/2lgMUiR
Please join Dr. Philip Baer for WEBINAR 2 of 2018 to be held Wednesday, June 20 at 8pm EST, focused on the recent article in Arthritis & Rheumatology by Tweehuysen et al:
Link to full text article: Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab
For webinar access details, see calendar invitation, or email sent to you on June 5.
If you have any comments or questions, please contact: